[Federal Register Volume 71, Number 159 (Thursday, August 17, 2006)]
[Notices]
[Page 47502]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-13502]



[[Page 47502]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Psychopharmacologic Drugs Advisory Committee; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    The Food and Drug Administration (FDA) is announcing an amendment 
to the notice of the meeting of the Psychopharmacologic Drugs Advisory 
Committee. The meeting was announced in the Federal Register of July 
20, 2006 (71 FR 41220). The amendment is being made to reflect a change 
in the Date and Time and Agenda portion of the notice. The Agenda 
scheduled for September 7, 2006, has been cancelled. The Agenda portion 
scheduled for September 8, 2006, has been moved to September 7, 2006. 
There are no other changes.

FOR FURTHER INFORMATION CONTACT: Cicely Reese, Center for Drug 
Evaluation and Research (HFD-21), Food and Drug Administration, 5600 
Fishers Lane (for express delivery, rm. 1093), Rockville, MD 20857, 
301-827-7001, FAX: 301-827-6776, e-mail: [email protected], or 
FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 
in the Washington, DC area), code 3014512544.

SUPPLEMENTARY INFORMATION: In the Federal Register of July 20, 2006, 
FDA announced that a meeting of the Psychopharmacologic Drugs Advisory 
Committee would be held on September 7, 2006, to discuss new drug 
application (NDA) 21-999, paliperidone extended-release (ER) tablets, 
Janssen, L.P./Johnson & Johnson Pharmaceutical Research and 
Development, L.L.C., proposed indication for treatment of schizophrenia 
and on September 8, 2006, to discuss NDA 21-992, desvenlafaxine 
succinate (DVS 233), ER tablets, Wyeth Pharmaceuticals, proposed 
indication for treatment of major depressive disorder. On page 41220, 
in the first column, the Date and Time portion of the meeting is 
amended to read as follows:
    Date and Time: The meeting will be held on September 7, 2006, from 
8 a.m. to 5 p.m.
    On page 41220, second column, the Agenda portion of the meeting is 
amended to read as follows:
    Agenda: On September 7, 2006, the committee will discuss new drug 
application (NDA) 21-992, desvenlafaxine succinate (DVS 233), extended-
release tablets, Wyeth Pharmaceuticals, proposed indication for 
treatment of major depressive disorder (MDD).
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

    Dated: August 8, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and Planning.
[FR Doc. E6-13502 Filed 8-16-06; 8:45 am]
BILLING CODE 4160-01-S